Lectin-Targeted Conjugates With Infection-Site Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotic conjugates face challenges with untimely degradation due to chemical or enzymatic activity in vivo, leading to severe side effects and reduced therapeutic efficacy, particularly in treating multi-resistant bacterial infections.
Innovation Solution
Development of lectin-targeted conjugates with a cleavable peptide-linker that specifically binds to bacterial lectins and is designed to be cleaved by bacterial proteases at the site of infection, ensuring targeted and controlled release of therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If a non-cleavable linker is used to conjugate the antibiotic to the lectin-targeting ligand, then the conjugate stability in plasma is improved, but the therapeutic efficacy at the infection site is reduced due to untimely release of the antibiotic
Solution Approach 1:
The linker is designed to be stable under normal plasma conditions but dynamically changes and becomes cleavable in the specific environment of the infection site where bacterial proteases are present. This dynamic behavior allows the system to adapt its stability characteristics based on the local environment, maintaining stability during circulation while enabling release at the target site.
Solution Approach 2:
The chemical state of the linker is changed by incorporating specific amino acid sequences that are substrates for bacterial proteases. This parameter change in the linker's molecular structure allows it to resist cleavage in plasma but undergoes enzymatic cleavage when exposed to bacterial proteases at the infection site, thereby controlling the timing and location of antibiotic release.
2Device complexity
If the antibiotic is released prematurely due to linker degradation, then the conjugate structure is simplified, but severe side effects occur and therapeutic efficacy is reduced
Solution Approach 1:
The bacterial protease acts as an intermediary that mediates the cleavage of the linker. Instead of the linker degrading spontaneously or through non-specific enzymatic activity, the release of the antibiotic is controlled by a specific bacterial enzyme that is present at the infection site. This intermediary mechanism ensures that the conjugate structure remains intact during circulation and only releases the antibiotic when the specific bacterial protease is encountered.
3Measurement precision
If a lectin-targeted conjugate with cleavable linker is designed, then the targeting precision and drug concentration at infection site are improved, but the complexity of the conjugate design increases
Solution Approach 1:
The conjugate design combines multiple functions into a single molecular construct: the lectin-targeting ligand provides specific binding to bacterial surfaces, the cleavable linker provides controlled release through protease cleavage, and the antibiotic provides therapeutic activity. This multi-functional design allows a single conjugate molecule to achieve targeting, controlled release, and therapeutic effect, thereby improving precision while managing complexity through functional integration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates provide improved stability, enhanced targeting, and higher drug concentration at the infection site, reducing systemic release and minimizing off-target effects, thereby increasing therapeutic efficacy and safety.
Implementation Method 1
R1 comprises one or more ligands specifically binding to a bacterial lectin
Implementation Method 2
Y is a linker comprising a peptide (Pep) cleavable by a bacterial protease
Implementation Method 3
Y is a linker comprising a peptide (Pep) cleavable by a bacterial protease
Data Source
AI summary
The present invention relates to a conjugate comprising a ligand specifically binding to a bacterial lectin, a linker comprising a peptide cleavable by a bacterial protease, and an anti-bacterial therapeutic agent or imaging agent. It further relates to the conjugate or the pharmaceutical composition or diagnostic composition for use in medicine.